Inhibitors of ret
US-2017121312-A1 · May 4, 2017 · US
Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
US11964980B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11964980-B2 |
| Application number | US-202218077466-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 8, 2022 |
| Priority date | Apr 12, 2019 |
| Publication date | Apr 23, 2024 |
| Grant date | Apr 23, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Crystalline Forms of Compound (I):pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
First claim
Opening claim text (preview).
The invention claimed is: 1. Crystalline Form A of Compound (I): characterized by an X-ray powder diffractogram which comprises at least three peaks at 2θ angles chosen from 11.5±0.2, 15.4±0.2, 16.7±0.2, 20.0±0.2, and 21.6±0.2. 2. The crystalline Form A according to claim 1 , characterized by an X-ray powder diffractogram which comprises at least seven peaks at 2θ angles chosen from 11.5±0.2, 15.4±0.2, 16.7±0.2, 18.1±0.2, 20.0±0.2, 21.6±0.2, 23.1±0.2, 23.9±0.2, 25.9±0.2, and 30.7±0.2. 3. The crystalline Form A according to claim 1 , characterized by an X-ray powder diffractogram which comprises at least eight peaks at 2θ angles chosen from 11.5±0.2, 15.4±0.2, 16.7±0.2, 18.1±0.2, 20.0±0.2, 21.6±0.2, 23.1±0.2, 23.9±0.2, 25.9±0.2, and 30.7±0.2. 4. The crystalline Form A according to claim 1 , characterized by an X-ray powder diffractogram which comprises peaks at 2θ angles of 11.5±0.2, 15.4±0.2, 16.7±0.2, 18.1±0.2, 20.0±0.2, 21.6±0.2, 23.1±0.2, 23.9±0.2, 25.9±0.2, and 30.7±0.2. 5. The crystalline Form A according to claim 1 , characterized by an X-ray powder diffractogram which comprises peaks at 2θ angles of 11.5±0.2, 15.4±0.2, 16.7±0.2, 20.0±0.2, and 21.6±0.2. 6. The crystalline Form A according to claim 1 , characterized by a DSC thermogram having an endothermic event with a signal at a temperature ranging from 194° C. to 195° C. or an onset temperature of 193° C. 7. A pharmaceutical composition comprising: at least one pharmaceutically acceptable excipient and the crystalline Form A of Compound (I) according to claim 1 .
Assignees
Inventors
Classifications
- A61K31/155Primary
Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
Drugs for dermatological disorders · CPC title
Antineoplastic agents · CPC title
Crystalline forms, e.g. polymorphs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11964980B2 cover?
- Crystalline Forms of Compound (I):pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
- Who is the assignee on this patent?
- Blueprint Medicines Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/155. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).